News

Mary Jo J. Fidler, MD, discusses intriguing data with pemetrexed in patients with nonsquamous non–small cell lung cancer.

The FDA has accepted an application for isatuximab for the treatment of patients with relapsed/refractory multiple myeloma.

The oral modified dysfunctional tyrosine SM-88 demonstrated a median overall survival of 6.4 months in patients with advanced pancreatic cancer.

James M. Rossetti, DO, discusses strategies for symptom management, tools available for risk stratification, and updated data with some of the pivotal agents in myeloproliferative neoplasms.

Mark E. Burkard, MD, PhD, discussed the significance of utilizing markers in the blood and highlighted emerging actionable mutations in breast cancer.

Rafic Farah, MD, provides an in-depth look at the trials that now define standards of care among patients with newly diagnosed and relapsed/refractory chronic lymphocytic leukemia.

Annie Im, MD, discusses the importance of minimal residual disease in acute lymphoblastic leukemia, the role of transplant, and novel treatment approaches under investigation.

The FDA has accepted 6 supplemental biologics license applications for review to update the dosing schedule for pembrolizumab (Keytruda) to include an every-6-weeks option at 400 mg over 30-minute infusions.

The quadruplet regimen of daratumumab, lenalidomide, bortezomib, and dexamethasone elicited a higher stringent complete response rate compared with lenalidomide, bortezomib, and dexamethasone alone in patients with transplant-eligible, newly diagnosed multiple myeloma, meeting the primary endpoint of the phase II GRIFFIN study.

Heather Wakelee, MD, discusses the rationale and findings for two combination regimens in EGFR-mutant non-small cell lung cancer, as well as the implications for our understanding of mechanisms of resistance.

Kari B. Wisinski, MD, highlights modern day approaches for treating patients with metastatic triple-negative breast cancer.

Anastasios Raptis, MD, highlights promising combinations under investigation in the frontline setting and remaining challenges in multiple myeloma.

Kleber Yotsumoto Fertrin, MD, PhD, provided insight into the new options that have emerged in the treatment landscape of benign hematologic malignancies.

Encorafenib, binimetinib, and cetuximab demonstrated a significant improvement in overall survival compared with cetuximab and an irinotecan-containing regimen in patients with BRAF-mutant colorectal cancer.

Robert L. Redner, MD, highlights some of the newer available agents in acute myeloid leukemia and ongoing studies that could impact clinical practice.

Robert C. Doebele, MD, PhD, discusses a retrospective trial comparing the efficacy of entrectinib with crizotinib in the treatment of patients with ROS1-positive non–small cell lung cancer.

Alison R. Sehgal, MD, discusses the latest developments with CAR T-cell therapy in lymphomas.

The FDA has granted an accelerated approval to selinexor in combination with dexamethasone for the treatment of adult patients with relapsed/refractory multiple myeloma who have received ≥4 prior therapies and whose disease is refractory to ≥2 proteasome inhibitors, ≥2 immunomodulatory agents, and a CD38-targeted monoclonal antibody.

Andrew J. Cowan, MD, discussed pivotal trials in multiple myeloma and potential for new treatments in the future.

A weekly regorafenib (Stivarga) dose-escalation strategy beginning at 80 mg and ending at 160 mg is an appropriate and potentially optimal approach for previously treated patients with metastatic colorectal cancer.

Vivian G. Oehler, MD, discusses the important aspects of TKI discontinuation and the patient factors that would warrant such an approach.

Vivian G. Oehler, MD, highlights ongoing developments in myeloproliferative neoplasms and shares her hopes for the future.

The CanStem111P trial, which was evaluating the combination of napabucasin, weekly nab-paclitaxel (Abraxane), and gemcitabine compared with nab-paclitaxel/gemcitabine alone in patients with metastatic pancreatic ductal adenocarcinoma, will be discontinued due to futility.

Chaitra S. Ujjani, MD, discusses the various therapeutic classes and agents that are showing the most promise in the field of follicular lymphoma.

Mary-Elizabeth Percival, MD, discusses advances and challenges with targeted agents in acute myeloid leukemia and remaining questions in the field.